Categories: Health

Antibody from common cold reacts to Covid infection: Study

<p>
<strong>US researchers have identified that a special type of antibody is produced in patients who've had Covid-19 as well as common colds, an advance that may be the starting point for broader-acting vaccines.</strong></p>
<p>
The study, by a team from the Scripps Research Institute, found that the cross-reactive antibody is produced by a memory B cell — an essential part of the immune system.</p>
<p>
They "remember" initial disease threats and can circulate in the bloodstream for decades, ready to be called back into action if the threat emerges again. These cells are responsible for producing targeted antibodies.</p>
<p>
"We were able to determine that this type of cross-reactive antibody is likely produced by a memory B cell that's initially exposed to a coronavirus that causes the common cold, and is then recalled during a Covid-19 infection," said senior author Raiees Andrabi, an investigator from the varsity's Department of Immunology and Microbiology.</p>
<p>
Using electron microscopy, the team investigated how the cross-reactive antibody is able to neutralise a range of coronaviruses. They examined blood samples collected before the pandemic and compared with samples from people who had been sick with Covid-19 and were able to pinpoint antibody types that cross reacted with benign coronaviruses as well as SARS-CoV-2.</p>
<p>
The findings, appearing in the journal Nature Communications, showed that prior exposure to a coronavirus, even a non-dangerous virus that causes colds can impact the nature and level of antibodies produced when more serious coronavirus threats emerge. The discovery will help in the pursuit of a vaccine or antibody treatment that works against most or all coronaviruses, the researchers said.</p>
<p>
Further tests revealed that the antibody also neutralised SARS-CoV-1, the coronavirus that causes SARS, or severe acute respiratory syndrome.</p>
<p>
The discovery may be an important step in the eventual development of a pan-coronavirus vaccine, which would be able to protect against potential coronaviruses that emerge in the future, Dennis Burton, Professor from the varsity.</p>
<p>
"Another deadly coronavirus will likely emerge again in the future — and when it does, we want to be better prepared. Our identification of a cross-reactive antibody against SARS-CoV-2 and the more common coronaviruses is a promising development on the way to a broad-acting vaccine or therapy," Burton noted.</p>

IANS

Recent Posts

India-UK FTA will propel bilateral trade, strengthen supply chains: Jaishankar during meeting with UK Foreign Secretary

Noting that the recent conclusion of the India-UK FTA and the Double Contribution Convention is…

1 day ago

“Strengthening early warning systems, coordination is crucial”, says PM Modi addressing ICDRI

Highlighting the significance of strengthening early warning systems to mitigate risks from disasters, Prime Minister…

1 day ago

Centre raises financial threshold for procurement of scientific equipment, consumables

The Central government has raised financial limits under the General Financial Rules (GFRs) for procurement…

2 days ago

Would be my pleasure to welcome PM Modi for G7: Former Canada MP Chandra Arya calls India “indispensable partner”

Former Member of Parliament of Canada, Chandra Arya, has said it would be his pleasure…

2 days ago

UK Foreign Secretary Lammy to meet PM Modi; to discuss bilateral economic and migration partnership

UK Foreign Secretary David Lammy will meet with Prime Minister Narendra Modi on his second…

2 days ago

“We can control any situation”: Gujarat Health Minister calls Omicron ‘not serious’, says all arrangements in place

Gujarat Health Minister Rushikesh Patel on Saturday noted that the state is fully prepared for…

2 days ago